|
- Daratumumab - Wikipedia
Daratumumab was granted breakthrough therapy drug status in 2013, for multiple myeloma It was granted orphan drug status for multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma
- Daratumumab (intravenous route) - Side effects uses
Daratumumab injection is used alone or together with other medicines to treat multiple myeloma (a type of bone marrow cancer)
- Daratumumab Information from Drugs. com
Daratumumab ( Darzalex) is used to treat multiple myeloma to help slow or stop cancer from progressing Daratumumab is a targeted cancer medicine that binds to a protein on the surface of myeloma cells, it then kills the cancer cells, and also helps the immune system to fight cancer better
- Daratumumab - NCI - National Cancer Institute
This page contains brief information about daratumumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials
- Daratumumab: a first-in-class CD38 monoclonal antibody for the . . .
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells
- DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)
What is DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj)? DARZALEX FASPRO ® is a prescription medicine used alone to treat adults with high-risk smoldering multiple myeloma (an early form of multiple myeloma that has a higher chance of progressing to active multiple myeloma)
- FDA Approval of SC Daratumumab: A Turning Point in High-Risk SMM
FDA approves daratumumab for high-risk smoldering multiple myeloma, transforming treatment strategies and enhancing patient outcomes in early intervention Smoldering multiple myeloma (SMM) is a heterogeneous precursor disease to active multiple myeloma (MM) in which risks of progression to active
- Daratumumab (DARZALEX) | FDA
On November 21, 2016, the U S Food and Drug Administration approved daratumumab (DARZALEX, Janssen Biotech, Inc ) in combination with lenalidomide and dexamethasone, or bortezomib and
|
|
|